Perspective Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 26, 2025

CATX$0.79-8.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

	Year Ended December 31,
	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$(79,279)	$(46,508)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense and amortization	2,306	986
Loss on disposal of property and equipment	27	22
Net accretion of discounts on available-for-sale securities	(607)	-
Loss on divestiture	59	4,170
Goodwill impairment	24,062	-
Share-based compensation	5,387	3,738
Deferred income tax benefit	(2,097)	(2,651)
Other, net	34	410
Changes in operating assets and liabilities:
Accounts receivable, net of allowance	1,049	198
Inventory related to discontinued operations (Note 5)	11	359
Interest receivable	(880)	-
Prepaid expenses and other current assets	(1,911)	(325)
Accounts payable and accrued expenses	1,890	1,573
Deferred Income1	28,000	-
Accrued personnel expenses	3,600	1,115
Other noncurrent liabilities	55	-
Net cash used in operating activities	(18,294)	(36,913)
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(54,414)	(1,072)
Proceeds from the sale of property and equipment	335	-
Additions to other assets	(72)	(18)
Purchases of available-for-sale securities	(164,780)	-
Proceeds from maturity of held-to-maturity investments	78,730	22,764
Purchases of held-to-maturity investments	(78,730)	-
Net cash acquired in acquisition of Viewpoint	-	2,699
Net cash (used in) provided by investing activities	(218,931)	24,373
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of notes payable	(48)	(68)
Proceeds from sales of common stock, pursuant to exercise of warrants, net	125	-
Proceeds from sales of common stock, pursuant to exercise of options	1,253	554
Proceeds from the issuance of common stock	275,807	364
Proceeds from the issuance of Pre-funded Warrants, net1	12,248	-
Issuance costs related to common stock issued in exchange for Viewpoint common stock	-	(65)
Net cash provided by financing activities	289,385	785
Net increase (decrease) in cash, cash equivalents and restricted cash	52,160	(11,755)
Cash, cash equivalents and restricted cash beginning of period	9,420	21,175
CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD	$61,580	$9,420
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents	$61,580	$9,238
Restricted cash	-	182
Total cash, cash equivalents and restricted cash shown on the consolidated statements of cash flows	$61,580	$9,420

See Note 3, Investments and Agreements, for additional information.

Consolidated Statements of Cash Flows, continued

	Year Ended December 31,
	2024	2023
Supplemental schedule of noncash investing and financing activities:
Recognition of operating lease liability and right-of-use asset	$2,115	$811
Modification of operating lease liability and right-of-use asset	-	557
Fair value of Viewpoint assets acquired including goodwill	-	82,628
13,654,5072 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock	-	(54,618)
Assumption of Viewpoint stock options and warrants at fair value	-	(7,836)
Note receivable and accrued interest from Viewpoint forgiven	-	(6,171)

Amount for prior period presented has been retroactively adjusted to reflect the 1-for-10 reverse stock split effected on June 14, 2024. See Note 1 for details.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.